» Articles » PMID: 22711850

Tumor-infiltrating Lymphocyte Grade is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients with Cutaneous Melanoma

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2012 Jun 20
PMID 22711850
Citations 408
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether density and distribution of tumor-infiltrating lymphocytes (TILs; TIL grade) is an independent predictor of sentinel lymph node (SLN) status and survival in patients with clinically localized primary cutaneous melanoma.

Methods: From the Melanoma Institute Australia database, 1,865 patients with a single primary melanoma ≥ 0.75 mm in thickness were identified. The associations of clinical and pathologic factors with SLN status, recurrence-free survival (RFS), and melanoma-specific survival (MSS) were analyzed.

Results: The majority of patients had either no (TIL grade 0; 35.4%) or few (TIL grade 1; 45.1%) TILs, with a minority showing moderate (TIL grade 2; 16.3%) or marked (TIL grade 3; 3.2%) TILs. Tumor thickness, mitotic rate, and Clark level were inversely correlated with TIL grade (each P < .001). SLN biopsy was performed in 1,138 patients (61.0%) and was positive in 252 (22.1%). There was a significant inverse association between SLN status and TIL grade (SLN positivity rates for each TIL grade: 0, 27.8%; 1, 20.1%; 2, 18.3%; 3, 5.6%; P < .001). Predictors of SLN positivity were decreasing age (P < .001), decreasing TIL grade (P < .001), ulceration (P = .003), increasing tumor thickness (P = .01), satellitosis (P = .03), and increasing mitoses (P = .03). The 5-year MSS and RFS rates were 83% and 76%, respectively (median follow-up, 43 months). Tumor thickness (P < .001), ulceration (P < .001), satellitosis (P < .001), mitotic rate (P = .003), TIL grade (P < .001), and sex (P = .01) were independent predictors of MSS. Patients with TIL grade 3 tumors had 100% survival.

Conclusion: TIL grade is an independent predictor of survival and SLN status in patients with melanoma. Patients with a pronounced TIL infiltrate have an excellent prognosis.

Citing Articles

A pan-cancer analysis of MARCH8: molecular characteristics, clinical relevance, and immuno-oncology features.

Quan Z, Fan S, Zheng H, Ning Y, Yang Y Cancer Biol Ther. 2025; 26(1):2458773.

PMID: 39881438 PMC: 11784653. DOI: 10.1080/15384047.2025.2458773.


Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.


Roles of cathepsin S expression levels on the prognosis and tumour microenvironment in clear cell renal cell carcinoma.

Wang X, Feng B, Guo H, Yao F, Song H, Wang X Discov Oncol. 2024; 15(1):690.

PMID: 39570472 PMC: 11582264. DOI: 10.1007/s12672-024-01547-3.


Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.

Jalil A, Donate M, Mattei J Cancer Drug Resist. 2024; 7:42.

PMID: 39534873 PMC: 11555183. DOI: 10.20517/cdr.2024.54.


Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.

Kefas J, Flynn M Cancer Drug Resist. 2024; 7:39.

PMID: 39534871 PMC: 11555186. DOI: 10.20517/cdr.2024.67.